Zika Vaccines 2023
Zika Vaccines For 2023
Zika vaccine candidate research has been active for the past few years, and previous study results suggest that a vaccine can be developed. The global Zika Vaccines Market is expanding due to the increased frequency of Zika virus infections.
Clinical trials involving DNA, modified vaccinia Ankara vector platform, and purified inactivated virus vaccines showed they were potentially safe and well-tolerated in small studies and induced neutralizing antibodies. However, the U.S. Food and Drug Administration (FDA) has not approved any Zika vaccine or treatment as of January 30, 2023.
Zika Vaccine Candidates 2023
TAK-426 (PIZV) is a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate. The Zika virus vaccine is being tested to provide safety and immunogenicity data to enable the vaccine to be further developed clinically.
mRNA-1893 contains an mRNA sequence encoding the structural proteins of the Zika virus. This phase 2 clinical study evaluates the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine compared to a placebo control in healthy participants flavivirus-seronegative and in participants who are flavivirus-seropositive. On January 19, 2023, a study concluded: These findings support the continued development of mRNA-1893 against Zika virus, which was well tolerated at all evaluated dose levels and induced strong Zika virus-specific serum nAb responses after two doses, regardless of baseline flavivirus serostatus.
GEO-ZM02 is constructed using a modified vaccinia Ankara vector platform. Preclinical studies demonstrated a single dose of GEO-ZM02 provided 100% protection against a lethal dose of the Zika virus. This Zika vaccine is based on the NS1 protein of Zika, which is not associated with Antibody-Dependent Enhancement of infection.
Ad26.ZIKV.001 is a replication-incompetent human adenovirus serotype 26 (ad26) vector vaccine candidate. In a clinical trial, researchers found two doses of Ad26.ZIKV.001 was safe, causing mild to moderate reactogenicity and induced persistent neutralizing antibody responses. The single dose had lower peak antibodies but was durable after one year.
ZPIV is a Zika virus vaccine candidate with purified formalin-inactivated Zika virus.
INO-A002 is a DNA-encoded monoclonal antibody (dMAb™) technology.
VLA1601 is a purified, inactivated, whole Zika virus vaccine candidate adsorbed on aluminum hydroxide.
VRC5283 is a Zika Virus DNA Vaccine candidate composed of a single closed-circular DNA plasmid-encoded with wild-type precursor transmembrane M and envelope proteins from the H/PF/2013 strain of ZIKV, conducting a phase 2 clinical study.
Zika Vaccine News For 2017 - 2023
January 25, 2023 - GeoVax Labs, Inc. confirmed the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, "Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein."
January 19, 2023 - The Lancet Infectious Disease published a study: The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomized, placebo-controlled, dose-ranging, phase 1 clinical trials. These findings support the continued development of mRNA-1893 against the ZIKV.
November 30, 2022 - Science Advances published a study: Zika virus noncoding RNA cooperates with the viral protein NS5 to inhibit STAT1 phosphorylation and facilitate viral pathogenesis. These results suggest the cooperation between viral noncoding RNA and a viral protein as a novel strategy for counteracting antiviral responses.
November 28, 2022 - Study - RT-PCR confirmed prenatal Zika virus exposure: a meta-analysis of cohorts in the Brazilian Cohorts Consortium.
August 4, 2022 - The Journal of Infectious Diseases published an Original Article: Why does Zika virus persist in the semen of some men but not others?
June 8, 2022 - A RESEARCH ARTICLE - Mosquito saliva enhances virus infection through sialokinin-dependent vascular leakage - The transmission of the virus from mosquito to vertebrate skin constitutes a significant bottleneck theatrical step for viruses to overcome. Factors that provide a replicative advantage for viruses at this crucial stage of infection are vital for defining the overall outcome.
January 27, 2022 - The peer-reviewed journal NPJ Vaccines published: Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets. 'These proof-of-concept studies demonstrate that ZPIV's protective efficacy is potent and durable and can potentially prevent the harmful consequence of ZIKV infection during pregnancy. Importantly, neutralizing antibody titers correlated with protecting dams and fetuses against ZIKV infection. '
December 9, 2021 - The U.S. CDC issued a Level 2 Travel Advisory for Uttar Pradesh, India.
November 7, 2021 - Researchers at the Institute of Medical Sciences in Bataras Hindu University have reported aan essential finding on Zika virus pathogenesis, which they claim, will help understand the molecular pathogenesis of the virus and in therapeutic development.
June 4, 2021 - BotTheuse and NHP challenge models were further standardized and refined by the ZIKAVAX consortium. "Based on the results, one of the vaccine candidates was selected for evaluation in NHP challenge studies for immunogenicity and efficacy, in comparison to a control vaccine and a first-generation MV-ZIKV vaccine," explains Frédéric Tangy, director of Research at the French National Centre for Scientific Research and head of the Viral Genomics and Vaccination Unit at Paris' Institut Pasteur. "Following the promising results in the preclinical animal models, the selected vaccine candidate was transitioned to further clinical development," adds Roger Le Grand, director of the IDMIT research department.
May 18, 2021 - The Lancet published a study that concluded that: TAK-426 was well tolerated, with an acceptable safety profile, and immunogenic in both flavivirus-naive and flavivirus-primed adults. Based on the safety and immunogenicity profiles of all TAK-426 doses assessed, the 10 μg TAK-426 amount was selected for further clinical development.
May 18, 2021 - The Lancet published a commentary on Zika vaccines: can we solve one problem without creating another? As viable Zika and dengue vaccines are made, it becomes crucial to understand how Zika and dengue immune interactions will affect subsequent flavivirus outbreaks and the use of Zika and dengue vaccines.
March 22, 2021 - Research study: Single-dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice.
February 18, 2021 - The Center for Infectious Disease Research and Policy at the University of Minnesota, the University of Texas Medical Branch, an expert team of task force members from around the world, and the World Health Organization have developed a draft Zika virus (ZIKV) Research and Development Roadmap. The roadmap is a vital component of the WHO's R&D Blueprint, a global strategy and preparedness plan that allows the activation of R&D activities in advance and during epidemics.
February 16, 2021 - The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector, showed promising safety and immunogenicity in the phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge.
October 29, 2020 - Genetic factors that reduce the placenta's capacity to protect a fetus from the Zika virus are described by Brazilian researchers in an article published in PLOS Neglected Tropical Diseases.
October 14, 2020 - Study published by The Lancet: Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies.
August 7, 2020 - A new study describes the preclinical selection and development of a potent ZIKV vaccine from 9 constructs using SAM technology expressing various forms of the ZIKV prM-E antigen. This study identified one ZIKV SAM vaccine candidate, VRC5283, that provided complete protection from the ZIKV challenge in mice and NHPs.
April 15, 2020 - Moderna's Zika vaccine mRNA1893 low dose levels were very effective.
January 23, 2020 - Researchers at the CUNY Graduate School of Public Health and Health Policy and the National School of Tropical Medicine at Baylor College of Medicine announced that they had developed a computer model representing the impact on a woman if she becomes infected with Zika, how it varies with pregnancy. The potential benefits of a vaccine to prevent Zika infection.
December 19, 2019 - A U.S. NIH-developed Zika vaccine improves fetal outcomes in an animal model.
December 13, 2019 - Researchers have made significant advances in developing a novel vaccine against the Zika virus, potentially leading to the global elimination of the disease.
December 11, 2019 - Study: NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice.
September 3, 2019 - Article: A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy.
January 17, 2019 - A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.
November 2, 2018 - Zika Virus Vaccine Development: Progress in the Face of New Challenges.
November 28, 2017 - Takeda Pharmaceutical announced that its purified, inactivated, alum-adjuvanted whole Zika virus vaccine candidate (TAK-426) has progressed into a Phase 1 clinical trial.
Vaccine Library Overview
The PrecisionVaccinations vaccine library includes new information from the U.S. FDA, European Medicines Agency, Brazil, Russia, India, China, and manyotherss.
Click here to access the A-Z vaccine library.
Note: Zika vaccine content sources include, but are not limited to, the World Health Organization, the US Centers for Disease Control and Prevention, clinicaltrials.gov, and the Precision Vaccinations news network. And this content has been reviewed by healthcare providers.